JP2021500855A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500855A5
JP2021500855A5 JP2020513914A JP2020513914A JP2021500855A5 JP 2021500855 A5 JP2021500855 A5 JP 2021500855A5 JP 2020513914 A JP2020513914 A JP 2020513914A JP 2020513914 A JP2020513914 A JP 2020513914A JP 2021500855 A5 JP2021500855 A5 JP 2021500855A5
Authority
JP
Japan
Prior art keywords
polypeptide
mhc class
terminal
tmapp
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/049760 external-priority patent/WO2019051094A1/en
Publication of JP2021500855A publication Critical patent/JP2021500855A/ja
Publication of JP2021500855A5 publication Critical patent/JP2021500855A5/ja
Priority to JP2024023312A priority Critical patent/JP2024063050A/ja
Pending legal-status Critical Current

Links

JP2020513914A 2017-09-07 2018-09-06 抗原提示ポリペプチドおよびその使用方法 Pending JP2021500855A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024023312A JP2024063050A (ja) 2017-09-07 2024-02-20 抗原提示ポリペプチドおよびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762555526P 2017-09-07 2017-09-07
US62/555,526 2017-09-07
US201862692314P 2018-06-29 2018-06-29
US62/692,314 2018-06-29
PCT/US2018/049760 WO2019051094A1 (en) 2017-09-07 2018-09-06 ANTIGEN PRESENTATION POLYPEPTIDES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024023312A Division JP2024063050A (ja) 2017-09-07 2024-02-20 抗原提示ポリペプチドおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2021500855A JP2021500855A (ja) 2021-01-14
JP2021500855A5 true JP2021500855A5 (enExample) 2021-10-14

Family

ID=65634574

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513914A Pending JP2021500855A (ja) 2017-09-07 2018-09-06 抗原提示ポリペプチドおよびその使用方法
JP2024023312A Pending JP2024063050A (ja) 2017-09-07 2024-02-20 抗原提示ポリペプチドおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024023312A Pending JP2024063050A (ja) 2017-09-07 2024-02-20 抗原提示ポリペプチドおよびその使用方法

Country Status (10)

Country Link
US (2) US20200172595A1 (enExample)
EP (1) EP3678677A4 (enExample)
JP (2) JP2021500855A (enExample)
KR (1) KR20200064083A (enExample)
CN (1) CN111278864A (enExample)
AU (1) AU2018328283A1 (enExample)
CA (1) CA3071881A1 (enExample)
IL (1) IL272332A (enExample)
TW (1) TW201920247A (enExample)
WO (1) WO2019051094A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475628A (zh) * 2016-05-18 2019-03-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
AU2017379900B2 (en) 2016-12-22 2024-12-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3935079A4 (en) * 2019-03-06 2023-03-22 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR ANTIGEN PRESENTING POLYPEPTIDES AND METHODS OF USE THEREOF
WO2020181272A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. MADCAM TARGETED IMMUNOTLERANCE
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
JP2023517595A (ja) * 2020-03-11 2023-04-26 アンブルックス,インコーポレイテッド インターロイキン-2ポリペプチド結合物およびその使用方法
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
WO2022056015A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof
WO2022056014A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
WO2022197971A1 (en) * 2021-03-19 2022-09-22 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
CN117222421A (zh) * 2021-03-19 2023-12-12 Cue生物制药股份有限公司 T细胞调节多肽和其使用方法
US20240189403A1 (en) * 2021-04-21 2024-06-13 Cue Biopharma, Inc. Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
CA3216278A1 (en) * 2021-04-21 2022-10-27 Iii Ronald D. Seidel Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
CN117327145A (zh) * 2022-06-24 2024-01-02 北京博辉瑞进生物科技有限公司 肽、肽修饰的sis膜、其制备方法及应用
CA3265696A1 (en) * 2022-09-12 2024-03-21 Cue Biopharma Inc Interleukin-2 polypeptides, fusion polypeptides, and their methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2783699A1 (en) * 2003-09-05 2014-10-01 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
MX2011007647A (es) * 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
SG10202006338UA (en) * 2014-06-18 2020-08-28 Albert Einstein College Medicine Inc Syntac polypeptides and uses thereof
CN107531805A (zh) * 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
US20190365656A1 (en) * 2016-01-04 2019-12-05 Cour Pharmaceuticals Development Company, Inc. Particles encapsulating fusion proteins containing linked epitopes
SG10202007639SA (en) * 2016-01-11 2020-09-29 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for immune indications
EP3423108A4 (en) * 2016-03-02 2019-10-02 Cue Biopharma, Inc. T CELL MODULATING MULTIPLE POLYPEPTIDES AND METHOD OF USE THEREOF
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인

Similar Documents

Publication Publication Date Title
JP2021500855A5 (enExample)
CN111148756B (zh) T细胞受体
KR102267345B1 (ko) T 세포 수용체
DK1935427T3 (en) APPLICATIONS OF SOLUBLE, MUTANT CTLA4 MOLECULES
JP5612623B2 (ja) 高親和性hivt細胞レセプター
JP2020511949A5 (enExample)
JP2020533273A5 (enExample)
JP2017527272A5 (enExample)
IL272085B2 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2019512222A5 (enExample)
JP2006502741A (ja) 単鎖組換えt細胞レセプター
JP2019522466A5 (enExample)
JP2021522835A (ja) 二機能性結合ポリペプチド
JP2019522465A5 (enExample)
JP7682927B2 (ja) 特異的結合性分子
CN106414482A (zh) T细胞受体
JP7742354B2 (ja) G12v変異を有するrasに対するhlaクラスii拘束性t細胞受容体
JP7313017B2 (ja) MHCクラスIaオープンコンフォーマー
JP2024517884A (ja) p53におけるC135Y、R175H又はM237I変異を認識するT細胞受容体
JPWO2020243315A5 (enExample)
WO2022008418A1 (en) Specific binding molecules
JPWO2020257191A5 (enExample)
JPWO2020132297A5 (enExample)
JPWO2020180501A5 (enExample)
JPWO2020181062A5 (enExample)